Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Aldeyra Therapeutics, Inc. - Common Stock (NQ:ALDX)

5.760 +0.200 (+3.60%)
Streaming Delayed Price Updated: 2:50 PM EDT, Sep 8, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Aldeyra Therapeutics, Inc. - Common Stock

< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
Aldeyra Therapeutics to Participate in Fireside Chat at the Jefferies Global Healthcare Conference
From Aldeyra Therapeutics, Inc.
Via Business Wire
Recap: Aldeyra Therapeutics Q1 Earnings
 
Via Benzinga
Aldeyra Therapeutics Reports First-Quarter 2023 Financial Results and Recent Corporate Highlights
From Aldeyra Therapeutics, Inc.
Via Business Wire
R&D Activities for Treating Dry Eye Syndrome Resulting in Promising Pipeline of Treatments
EQNX::TICKER_START (NASDAQ:OKYO),(NYSE:NVS),(NASDAQ:ALDX),(NASDAQ:OCUL),(NASDAQ:EYPT) EQNX::TICKER_END 
Via FinancialNewsMedia
Earnings Outlook For Aldeyra Therapeutics
 
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
 
Via Benzinga
The Week In Charts: 0DTE Options - Too Good To Be True?
Zero-days; how Core Methodology can be used in Crypto, with current Crypto and stock market conditions; favorite stock picks. 
Via Talk Markets
Short Volatility Alert: Aldeyra Therapeutics
On Thursday, shares of Aldeyra Therapeutics (NASDAQ: ALDX) experienced volatile short activity. After the activity, the stock price went down -0.22% to $9.05. The overall sentiment for ALDX has been... 
Via Benzinga
OKYO Pharma Management Takes Company Stock In Private Placement Instead Of Deferred Pay
Drug development can be notoriously slow, and it can take some companies 10 years or more to pass through all the trials and tests required by the Food and Drug Administration (FDA). 
Via Benzinga
Aldeyra Therapeutics Completes Enrollment in Phase 3 INVIGORATE-2 Clinical Trial in Allergic Conjunctivitis
From Aldeyra Therapeutics, Inc.
Via Business Wire
Chart Of The Day: Aldeyra - Skyrocketing
Revenue is expected to grow by 2,045.80% next year. Earnings are estimated to increase by 16.90% next year and continue to compound at an annual rate of 73.70% for the next 5 years. 
Via Talk Markets
Aldeyra Therapeutics Inc. (NASDAQ: ALDX) Records 52-Week High Monday Morning
Via Investor Brand Network
Aldeyra Therapeutics Enrolls First Patient in Phase 2 Clinical Trial of ADX-629 in Atopic Dermatitis
From Aldeyra Therapeutics, Inc.
Via Business Wire
Aldeyra Therapeutics Announces Completion of Enrollment in Phase 2 Clinical Trial of ADX-629 in Chronic Cough
From Aldeyra Therapeutics, Inc.
Via Business Wire
OKYO Pharma To Begin Phase 2 Efficacy Trials For Dry Eye Disease Drug Candidate In March 2023, Anticipates Releasing Topline Results By Q4
Drug development isn’t known for being fast-paced, and developing any new drug is generally a long process. However, OKYO Pharma Ltd. (NASDAQ: OKYO) is moving quickly to develop its eye treatment drug,... 
Via Benzinga
BioNTech, Coinbase Global, Pharming Group And Other Big Stocks Moving Lower On Monday
U.S. stocks traded higher, with the Dow Jones gaining around 200 points on Monday. Here are some big stocks recording losses in today’s session. 
Via Benzinga
UBS, Credit Suisse And Other Big Stocks Moving Lower In Friday's Pre-Market Session
U.S. stock futures traded lower this morning. Here are some big stocks recording losses in today’s pre-market trading session. 
Via Benzinga
KB Home, Accenture, Netflix And Other Big Stocks Moving Higher On Thursday
U.S. stocks traded higher, with the Dow Jones gaining around 200 points on Thursday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Aldeyra Therapeutics Announces Completion of Enrollment in Phase 2 Clinical Trial of ADX‑2191 in Retinitis Pigmentosa
From Aldeyra Therapeutics, Inc.
Via Business Wire
Aldeyra Therapeutics Reports Full-Year 2022 Financial Results and Recent Corporate Highlights
From Aldeyra Therapeutics, Inc.
Via Business Wire
FDA Accepts for Priority Review ADX-2191 New Drug Application for the Treatment of Primary Vitreoretinal Lymphoma
From Aldeyra Therapeutics, Inc.
Via Business Wire
Aldeyra Therapeutics Schedules Webcast and Conference Call to Report Full-Year 2022 Financial Results and Discuss Recent Corporate Highlights
From Aldeyra Therapeutics, Inc.
Via Business Wire
Aldeyra Highlights 12-Month Safety Data Of Reproxalap In Dry Eye Disease Patients
 
Via Benzinga
Aldeyra Therapeutics Announces Positive Top-Line Results from 12-Month Safety Clinical Trial of Reproxalap in Patients with Dry Eye Disease
From Aldeyra Therapeutics, Inc.
Via Business Wire
Bio-Pharma Company OKYO Pharma Tackles A Common Eye Disease For Which The Current Treatments Aren't Effective Enough
An eye condition that has been described as a stealth disease currently affects as many as 49 million Americans. Dry Eye Disease (DED) afflicts over one-third of Americans over 50 and... 
Via Benzinga
Aldeyra Therapeutics Announces Next-Generation RASP-Modulator Drug Candidates Expected to Begin Clinical Trials for Systemic Immune-Mediated Diseases and Geographic Atrophy
From Aldeyra Therapeutics, Inc.
Via Business Wire
Aldeyra Therapeutics Advances Investigational Oral RASP Modulator ADX‑629 Into New Phase 2 Systemic Disease Trials
From Aldeyra Therapeutics, Inc.
Via Business Wire
Aldeyra Therapeutics to Participate in Fireside Chat at the SVB Securities Global Biopharma Conference
From Aldeyra Therapeutics, Inc.
Via Business Wire
Aldeyra Therapeutics Announces FDA Acceptance of New Drug Application for Reproxalap for the Treatment of Dry Eye Disease
From Aldeyra Therapeutics, Inc.
Via Business Wire
Aldeyra Therapeutics Submits New Drug Application to the U.S. Food and Drug Administration for ADX‑2191 for the Treatment of Primary Vitreoretinal Lymphoma
From Aldeyra Therapeutics, Inc.
Via Business Wire
< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.